Importantly, in cancer patients, TLR9 expression is not limited to plasmacytoid DCs and B cells as in healthy subjects but is upregulated in PMN-MDSCs, which are the dominant tolerogenic cell population accumulating in the blood of patients with various cancers [50,53,93]. Here, TLR9 is linked to cancer.